Berlin, Germany

Thomas Specht

This inventor holds 1 USPTO granted patent. Top assignee: Metagen Pharmaceuticals Gmbh. Active years: 2003.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas Specht: Innovator in Nucleic Acid Research

Introduction

Thomas Specht is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of molecular biology, particularly in the study of human nucleic acid sequences. His work has implications for understanding endometrial tumors and their genetic underpinnings.

Latest Patents

Thomas Specht holds a patent for "Human nucleic acid sequences from endometrial tumor tissue." This patent describes human nucleic acid sequences, including mRNA, cDNA, and genomic sequences derived from endometrial tumor tissue. These sequences code for gene products or portions thereof, and their potential applications are also outlined. Additionally, the patent discusses the polypeptides that can be obtained from these sequences and their uses in research and medicine.

Career Highlights

Thomas Specht is associated with Metagen Pharmaceuticals GmbH, where he continues to advance his research in the field. His work is pivotal in exploring the genetic factors associated with endometrial tumors, contributing to the broader understanding of cancer biology.

Collaborations

Some of his notable coworkers include Armin Schmitt and Christian Pilarsky. Their collaborative efforts enhance the research output and innovation at Metagen Pharmaceuticals GmbH.

Conclusion

Thomas Specht's contributions to the field of nucleic acid research are significant, particularly in the context of endometrial tumors. His patent and ongoing work at Metagen Pharmaceuticals GmbH highlight his role as an innovator in this critical area of study.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…